Literature DB >> 25878100

Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.

Laura K Pritchard1, Daniel I R Spencer2, Louise Royle2, Snezana Vasiljevic1, Stefanie A Krumm3, Katie J Doores3, Max Crispin4.   

Abstract

Broadly neutralizing antibodies have been isolated that bind the glycan shield of the HIV-1 envelope spike. One such antibody, PGT135, contacts the intrinsic mannose patch of gp120 at the Asn332, Asn392, and Asn386 glycosylation sites. Here, site-specific glycosylation analysis of recombinant gp120 revealed glycan microheterogeneity sufficient to explain the existence of a minor population of virions resistant to PGT135 neutralization. Target microheterogeneity and antibody glycan specificity are therefore important parameters in HIV-1 vaccine design.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25878100      PMCID： PMC4468474          DOI： 10.1128/JVI.00230-15

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  43 in total

1.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells.

Authors:  X Zhu; C Borchers; R J Bienstock; K B Tomer
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

2.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

4.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Authors:  Louise Scharf; Johannes F Scheid; Jeong Hyun Lee; Anthony P West; Courtney Chen; Han Gao; Priyanthi N P Gnanapragasam; René Mares; Michael S Seaman; Andrew B Ward; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

5.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Authors:  Claudia Blattner; Jeong Hyun Lee; Kwinten Sliepen; Ronald Derking; Emilia Falkowska; Alba Torrents de la Peña; Albert Cupo; Jean-Philippe Julien; Marit van Gils; Peter S Lee; Wenjie Peng; James C Paulson; Pascal Poignard; Dennis R Burton; John P Moore; Rogier W Sanders; Ian A Wilson; Andrew B Ward
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

6.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.

Authors:  Emilia Falkowska; Khoa M Le; Alejandra Ramos; Katie J Doores; Jeong Hyun Lee; Claudia Blattner; Alejandro Ramirez; Ronald Derking; Marit J van Gils; Chi-Hui Liang; Ryan Mcbride; Benjamin von Bredow; Sachin S Shivatare; Chung-Yi Wu; Po-Ying Chan-Hui; Yan Liu; Ten Feizi; Michael B Zwick; Wayne C Koff; Michael S Seaman; Kristine Swiderek; John P Moore; David Evans; James C Paulson; Chi-Huey Wong; Andrew B Ward; Ian A Wilson; Rogier W Sanders; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2014-04-24       Impact factor: 31.745

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

Authors:  Devin Sok; Katie J Doores; Bryan Briney; Khoa M Le; Karen L Saye-Francisco; Alejandra Ramos; Daniel W Kulp; Jean-Philippe Julien; Sergey Menis; Lalinda Wickramasinghe; Michael S Seaman; William R Schief; Ian A Wilson; Pascal Poignard; Dennis R Burton
Journal:  Sci Transl Med       Date:  2014-05-14       Impact factor: 17.956

10.  Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.

Authors:  Katie J Doores; Leopold Kong; Stefanie A Krumm; Khoa M Le; Devin Sok; Uri Laserson; Fernando Garces; Pascal Poignard; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103
View more
  26 in total

1.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 2.  Antibody recognition of HIV and dengue glycoproteins.

Authors:  Isaac J Krauss
Journal:  Glycobiology       Date:  2016-03-03       Impact factor: 4.313

3.  Structure and Immune Recognition of the HIV Glycan Shield.

Authors:  Max Crispin; Andrew B Ward; Ian A Wilson
Journal:  Annu Rev Biophys       Date:  2018-03-29       Impact factor: 12.981

Review 4.  Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.

Authors:  Anna-Janina Behrens; Weston B Struwe; Max Crispin
Journal:  Expert Rev Proteomics       Date:  2017-09-14       Impact factor: 3.940

5.  Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.

Authors:  Kostyantyn D Bobyk; Sivakoteswara R Mandadapu; Katheryn Lohith; Christina Guzzo; Abhishek Bhargava; Paolo Lusso; Carole A Bewley
Journal:  Mol Pharm       Date:  2017-07-13       Impact factor: 4.939

Review 6.  Harnessing post-translational modifications for next-generation HIV immunogens.

Authors:  Joel D Allen; Rogier W Sanders; Katie J Doores; Max Crispin
Journal:  Biochem Soc Trans       Date:  2018-05-21       Impact factor: 5.407

7.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.

Authors:  Anna-Janina Behrens; David J Harvey; Emilia Milne; Albert Cupo; Abhinav Kumar; Nicole Zitzmann; Weston B Struwe; John P Moore; Max Crispin
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

8.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer.

Authors:  Jeong Hyun Lee; Gabriel Ozorowski; Andrew B Ward
Journal:  Science       Date:  2016-03-04       Impact factor: 47.728

9.  Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.

Authors:  Boris Julg; Devin Sok; Stephen D Schmidt; Peter Abbink; Ruchi M Newman; Thomas Broge; Caitlyn Linde; Joseph Nkolola; Khoa Le; David Su; Julia Torabi; Melissa Pack; Amarendra Pegu; Todd M Allen; John R Mascola; Dennis R Burton; Dan H Barouch
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

10.  Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.

Authors:  Laura E McCoy; Emilia Falkowska; Katie J Doores; Khoa Le; Devin Sok; Marit J van Gils; Zelda Euler; Judith A Burger; Michael S Seaman; Rogier W Sanders; Hanneke Schuitemaker; Pascal Poignard; Terri Wrin; Dennis R Burton
Journal:  PLoS Pathog       Date:  2015-08-12       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.